Search

Sygnature Chemical Services Ltd., a leading provider of medicinal and computational chemistry services to the global pharmaceutical industry, and Cyprotex Discovery Ltd., a world renowned pre-clinical discovery and development CRO with a core focus on ADME/PK, today announced they have entered a strategic alliance. Under the terms of the agreement, Sygnature and Cyprotex will collaborate to provide a fully integrated discovery chemistry/DMPK service to accelerate their clients' drug discovery projects into development.